NO963213L - Endotelinreseptorantagonister - Google Patents
EndotelinreseptorantagonisterInfo
- Publication number
- NO963213L NO963213L NO963213A NO963213A NO963213L NO 963213 L NO963213 L NO 963213L NO 963213 A NO963213 A NO 963213A NO 963213 A NO963213 A NO 963213A NO 963213 L NO963213 L NO 963213L
- Authority
- NO
- Norway
- Prior art keywords
- unsubstituted
- coor6
- hal
- independently
- group
- Prior art date
Links
- 102000002045 Endothelin Human genes 0.000 title 1
- 108050009340 Endothelin Proteins 0.000 title 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 101100134925 Gallus gallus COR6 gene Proteins 0.000 abstract 2
- -1 1H-tetrazol-5-yl Chemical group 0.000 abstract 1
- 102000010180 Endothelin receptor Human genes 0.000 abstract 1
- 108050001739 Endothelin receptor Proteins 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 abstract 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Nye forbindelser med formel I hvor -Y-Z- er -NR7-CO-, -N=C(OR7)- eller -N=CR8-; R1 er Ar; R2 er COOR6, (CH2)nCOOR6, CN, lH-tetrazol-5-yl eller CONHS02Ar; R3, R4 og R5 er uavhengig av hverandre R6, OR6, S(O),,R6, Hal, N02, NR6R6', NHCOR6, NHSO2R6, OCOR6, COR6, COOR6 eller CN, idet R3 og R4 til sammen også kan utgjøre en O(CH2)nO-gruppe; R6 og R6' er uavhengig av hverandre H, alkyl med 1-6 C-atomer, benzyl eller fenyl; R7 er (CH2)nAr; R8 er Ar eller OAr; Ar er usubstituert eller en, to eller tre ganger med R9, R10 eller R11 substituert fenyl, eller usubstituert naftyl eller en usubstituert eller i fenyldelen en eller to ganger med R9 eller R10 substituert D-gruppe eller en usubstituert eller i sykloheksadien- yldelen en eller to ganger med R9 eller substituert N X-gruppe, R9, R10 og R11 er uavhengig av hverandre R6, OR6, Hal, CF3, OCF3, OCHF2, OCH2F, N02, NR6R6', NHCOR6, CN, NHS02R6, COOR6, COR6, CONHS02Ar, O(CH2)nR2, 0(CH2)nOR6 eller S(0)nR6; E er CH2, S eller O; D er karbonyl eller [C(R6R6')]n; X er O eller S; Hal er F, Cl, Br eller I; m er O, l eller 2; og n er l, 2 eller 3; samt deres salter, utviser endotelin- reseptorantagonistiske egenskaper .
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19528418A DE19528418A1 (de) | 1995-08-02 | 1995-08-02 | Endothelin-Rezeptor-Antagonisten |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO963213D0 NO963213D0 (no) | 1996-08-01 |
| NO963213L true NO963213L (no) | 1997-02-03 |
Family
ID=7768528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO963213A NO963213L (no) | 1995-08-02 | 1996-08-01 | Endotelinreseptorantagonister |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5731321A (no) |
| EP (1) | EP0757039A1 (no) |
| JP (1) | JPH0940649A (no) |
| KR (1) | KR970010746A (no) |
| AR (1) | AR004675A1 (no) |
| AU (1) | AU705959B2 (no) |
| BR (1) | BR9603252A (no) |
| CA (1) | CA2182469A1 (no) |
| CZ (1) | CZ224096A3 (no) |
| DE (1) | DE19528418A1 (no) |
| HU (1) | HUP9602127A1 (no) |
| MX (1) | MX9603199A (no) |
| NO (1) | NO963213L (no) |
| PL (1) | PL315479A1 (no) |
| SK (1) | SK100296A3 (no) |
| ZA (1) | ZA966552B (no) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251861B1 (en) * | 1996-06-27 | 2001-06-26 | Takeda Chemical Industries, Ltd. | Treatment of cerebral infarction using cyclic hexapeptides |
| DE19839499A1 (de) * | 1998-08-29 | 2000-03-02 | Merck Patent Gmbh | 2-Oxo-2H-chinolinderivate |
| DE10155076A1 (de) * | 2001-11-09 | 2003-05-22 | Merck Patent Gmbh | Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen |
| CA2539760C (en) * | 2003-09-23 | 2011-01-25 | Merck & Co., Inc. | Quinoline potassium channel inhibitors |
| US7939545B2 (en) * | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| US8377949B2 (en) * | 2007-08-16 | 2013-02-19 | Boehringer Ingelheim International Gmbh | Quinazolinedione chymase inhibitors |
| SI2220076T1 (sl) * | 2007-11-15 | 2012-05-31 | Gilead Sciences Inc | Inhibitorji replikacije virusa humane imunske pomankljivosti |
| US8354429B2 (en) | 2007-11-16 | 2013-01-15 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1336714C (en) * | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
| US5514691A (en) * | 1993-05-20 | 1996-05-07 | Immunopharmaceutics, Inc. | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| RU2086544C1 (ru) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| GB9115153D0 (en) * | 1991-07-12 | 1991-08-28 | Patel Bipin C M | Sol-gel composition for producing glassy coatings |
| DE4208304A1 (de) * | 1992-03-16 | 1993-09-23 | Merck Patent Gmbh | 2-oxochinolinderivate |
| US5565472A (en) * | 1992-12-21 | 1996-10-15 | Pfizer Inc. | 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents |
| ZA939516B (en) * | 1992-12-22 | 1994-06-06 | Smithkline Beecham Corp | Endothelin receptor antagonists |
| ES2141197T3 (es) * | 1993-03-19 | 2000-03-16 | Merck & Co Inc | Derivados del acido fenoxifenilacetico. |
| JPH06340658A (ja) * | 1993-04-08 | 1994-12-13 | Kyowa Hakko Kogyo Co Ltd | ベンゾイミダゾール誘導体 |
| JPH09501915A (ja) * | 1993-08-06 | 1997-02-25 | スミスクライン・ビーチャム・コーポレイション | エンドセリン受容体アンタゴニスト |
| DE4341663A1 (de) * | 1993-12-07 | 1995-06-08 | Basf Ag | Anellierte 2-Oxopiperazine, ihre Herstellung und Verwendung |
-
1995
- 1995-08-02 DE DE19528418A patent/DE19528418A1/de not_active Withdrawn
-
1996
- 1996-07-29 CZ CZ962240A patent/CZ224096A3/cs unknown
- 1996-07-29 AU AU60792/96A patent/AU705959B2/en not_active Ceased
- 1996-07-31 EP EP96112347A patent/EP0757039A1/de not_active Withdrawn
- 1996-07-31 CA CA002182469A patent/CA2182469A1/en not_active Abandoned
- 1996-07-31 SK SK1002-96A patent/SK100296A3/sk unknown
- 1996-08-01 US US08/691,148 patent/US5731321A/en not_active Expired - Fee Related
- 1996-08-01 HU HU9602127A patent/HUP9602127A1/hu unknown
- 1996-08-01 PL PL96315479A patent/PL315479A1/xx unknown
- 1996-08-01 BR BR9603252A patent/BR9603252A/pt not_active Application Discontinuation
- 1996-08-01 NO NO963213A patent/NO963213L/no unknown
- 1996-08-01 ZA ZA9606552A patent/ZA966552B/xx unknown
- 1996-08-01 KR KR1019960032224A patent/KR970010746A/ko not_active Withdrawn
- 1996-08-02 MX MX9603199A patent/MX9603199A/es unknown
- 1996-08-02 JP JP8219113A patent/JPH0940649A/ja active Pending
- 1996-08-02 AR ARP960103850A patent/AR004675A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU9602127D0 (en) | 1996-09-30 |
| PL315479A1 (en) | 1997-02-03 |
| AU705959B2 (en) | 1999-06-03 |
| BR9603252A (pt) | 1998-04-28 |
| US5731321A (en) | 1998-03-24 |
| AR004675A1 (es) | 1999-03-10 |
| CZ224096A3 (en) | 1997-02-12 |
| EP0757039A1 (de) | 1997-02-05 |
| NO963213D0 (no) | 1996-08-01 |
| CA2182469A1 (en) | 1997-02-03 |
| MX9603199A (es) | 1997-07-31 |
| SK100296A3 (en) | 1997-03-05 |
| AU6079296A (en) | 1997-02-06 |
| HUP9602127A1 (hu) | 1998-05-28 |
| KR970010746A (ko) | 1997-03-27 |
| ZA966552B (en) | 1997-02-18 |
| DE19528418A1 (de) | 1997-02-06 |
| JPH0940649A (ja) | 1997-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0862567T3 (da) | 5-azabicyclo[3.1.0]hexylalkyl-2-piperidoner og-glutarimider som neurokininreceptorantagonister | |
| HRP20020175B1 (hr) | N-heterociklički derivati kao inhibitori nos | |
| KR950704313A (ko) | 5-아릴인돌 유도체 및 세로토닌(5-ht₁)작용물질로서의 그의 용도(5-arylindole derivatives and their use as serotonin(5-ht₁)agonists) | |
| ATE282614T1 (de) | Phenylharnstoff und phenylthioharnstoffderivate | |
| NO912739L (no) | Nye 3-arylindol- og 3-arylindazolderivater. | |
| YU59601A (sh) | Derivati piridopiranoazepina, njihovo pripremanje i terapeutska primena | |
| ATE359073T1 (de) | Benzylidenthiazolidindione und ihre verwendung als antimykotische mittel | |
| IL119828A (en) | 6-(disubstituted amino)-2,4-¬(bis(hydroxyaryl)¾-1,3,5-triazine derivatives their preparation and cosmetic light-screening agents containing them | |
| ATE182889T1 (de) | Bicyclische amidinderivate als no-synthetase inhibitoren | |
| PT1021405E (pt) | Derivados de azetidinona para o tratamento de infeccoes de hcmv | |
| ATE374748T1 (de) | Phenylcyclohexylpropanolaminderivate, deren herstellung und therapeutsche anwendung | |
| NO943961L (no) | Sykliske aminderivater | |
| ES2099180T3 (es) | Derivados del benzopirano y procedimientos para su preparacion. | |
| TR200001926T2 (tr) | Vasküler başağrılarına karşı lokal anesteziklerin yeni kullanımı | |
| NZ334966A (en) | Substituted arylalkylamines as neurokinin antagonists | |
| DE69909811T2 (de) | Substituierte isoxazolylthiophenverbindungen | |
| RU94016363A (ru) | Производные 2-аминопиразин 5-карбоксамида, их получение и применение в терапии | |
| ES2154191A1 (es) | Nuevos acetales derivados de los 2-alquil-5-halo-3-(2'-(tetrazol-5-il)-bifenil-4-ilmetil)-3h-imidazol-4-carbaldehidos. | |
| HRP20080501T3 (en) | Beta-lactams for the treatment of cns disorders | |
| TH34361A (th) | สารประกอบ | |
| MX9804482A (es) | Quinolinas y quinazolinas utiles en terapias. | |
| AR003970A1 (es) | Nuevos compuestos antagonistas de receptores de endotelina, procedimiento para prepararlos, composiciones farmaceuticas que los contienen y procedimientopara preparar estas composiciones farmaceuticas. | |
| DE68911893D1 (de) | Antagonisten von Leukotrien D4. |